ALPI Solutions

10/21/2026

Could AI help connect more patients with clinical trials?

Today, AstraZeneca and Oracle announced plans to explore how AI and real-world data could help identify potential trial participants and bring research insights into everyday care.

The collaboration is still at an early stage, and its impact will need to be evaluated.

At ALPI Solutions, we see an important planning question behind this news: what will research teams need to make these tools useful?

Reliable data, prepared sites, clear responsibilities, and realistic budgets should all be part of that discussion.

Where do you see the greatest potential for AI in clinical research?

Read the announcement:
https://www.oracle.com/news/announcement/oracle-and-astrazeneca-partner-to-advance-ai-enabled-healthcare-2026-10-20/

The collaboration is expected to combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data infrastructure, cloud, AI, analytics, and clinical workflow capabilities.

05/19/2026

Over the past few weeks, the pharmaceutical industry has been discussing one major topic: the future of FDA regulation in the AI era.
The FDA is actively exploring:�
• AI-assisted clinical trial monitoring�
• Real-time clinical data review�
• Faster regulatory pathways�
• New frameworks for AI-based decision-making in drug development
At the same time, recent leadership changes and ongoing regulatory uncertainty are creating new challenges for pharma and biotech companies.
What does this mean for the industry?
Speed is becoming a competitive advantage.�But speed without regulatory strategy creates risk.
Companies now need not only innovation, but also:�
✔ strong regulatory planning�
✔ inspection readiness�
✔ compliant AI implementation�
✔ high-quality documentation and evidence generation�
✔ clear communication with regulators
We are entering a new phase where pharma consulting is no longer “optional support” — it becomes part of strategic survival and growth.
At ALPI Solutions, we closely monitor global regulatory trends, AI integration in pharma, and evolving FDA/EMA expectations to help companies navigate an increasingly complex environment.
The future of pharma will belong to companies that can combine:�innovation + compliance + adaptability.
What trend do you think will reshape pharma the most in the next 3–5 years: AI, pricing pressure, personalized medicine, or regulatory transformation?

04/14/2026

ABM in Pharma isn’t a “nice-to-have” anymore — it’s a must-have in 2026.
We’ve all felt it: the old way of doing things — blasting out webinars and chasing generic leads — just isn’t cutting it like before.
Decision committees are bigger, sales cycles are longer, and trust matters way more than just being visible.
That’s why smart pharma and biotech companies are turning to Account-Based Marketing (ABM).
Why it’s working so well right now:
• 81% of life sciences companies are seeing much higher ROI with ABM
• Mature ABM programs deliver +38% win rates and +24% revenue growth
• Instead of spraying and praying, you deeply focus on the 10–50 accounts that actually matter
In pharma, ABM means treating every key account like its own market — really understanding their regulatory challenges, mapping the full decision team, and moving from just giving advice to sharing ownership of the results.
At ALPI Solutions, here’s how we’re doing it:
We don’t chase volume. We choose precision.
For the right accounts, we create personalized insights, custom risk assessments, and joint sessions that actually help move projects forward faster and with less risk.
The outcome? Shorter sales cycles, better win rates, and real strategic partnerships.

The game has changed:
From broad reach → to deep, focused impact.
Who else is using (or thinking about) ABM in pharma or life sciences?
Drop a comment below 👇
What’s your experience with it so far?

04/02/2026

GLP-1 therapies are rapidly reshaping the market — and it’s no longer just a clinical story.

What we’re seeing today goes far beyond weight loss or diabetes treatment.

It’s a broader shift across the entire pharmaceutical landscape:

— increased regulatory focus on long-term safety and real-world evidence
— growing pressure on pricing and market access
— expansion into obesity and metabolic health
— rising demand for better physician engagement and patient education

For pharmaceutical companies, this creates new challenges:

— how to adapt regulatory strategies
— how to align field force teams with evolving product positioning
— how to navigate a fast-changing and highly competitive market
— how to generate meaningful, actionable insights

At ALPI Solutions, we work exactly at this intersection:

🔹 Regulatory Affairs
🔹 Field Force effectiveness
🔹 Market Research
🔹 Product strategy and market expansion

Understanding trends is no longer enough.
What matters is how you respond to them.

💬 Do you think the GLP-1 market is reaching saturation — or just getting started?

03/23/2026

Artificial Intelligence is no longer something “in development” in pharma — it is already becoming part of everyday practice.

At the Pharma USA meeting in March 2026, industry experts discussed how AI is being integrated into real processes — from research to operational and commercial functions — with one clear goal: bringing therapies to patients faster.

🔗 Source: https://www.bioworld.com/articles/729563-pharma-usa-folding-ai-into-the-gameplan-to-speed-research-adoption?v=preview

What does this mean in reality?

Pharmaceutical companies are no longer just testing AI — they are actively implementing it, building partnerships, and redesigning how decisions are made.

This is a turning point for the industry.

It also changes the role of many functions — including regulatory strategy, field force, and market access.

At ALPI Solutions, we believe that success today depends not only on innovation, but on how effectively it is integrated into real-world processes.

02/19/2026

Field Force 2026: reps don’t disappear. They evolve.

Pharma used to measure success by one thing:
“How many visits did we make this week?” But that model is changing.
Today it’s about:

• smarter targeting
• data before territory
• hybrid meetings (digital + in-person)
• real clinical conversations instead of product monologues

Doctors are overloaded.
Time is limited.
Data matters more than repetition.

The strongest field teams in 2026 aren’t the busiest.
They’re the most precise.
Pharma is moving from “more visits” to “better impact.”
And that shift is permanent.

02/12/2026

ALPI Solutions at MD&M West 2026 | Key Takeaways
Last week, the ALPI Solutions team attended MD&M West 2026 in Anaheim, one of the most important industry exhibitions at the intersection of medical devices, manufacturing, and regulatory affairs.
For us, MD&M is not just about technologies — it’s about understanding how regulatory expectations translate into real devices, real manufacturing processes, and real compliance decisions.
What stood out most:
• Regulatory Affairs is becoming a strategic function, deeply integrated into design, materials, and manufacturing
• Strong focus on traceability, data integrity, design controls, and lifecycle compliance
• Increasing complexity of medical devices and multi-vendor supply chains, raising new regulatory challenges
• Practical, experience-based sessions discussing real inspection findings and compliance pitfalls
• A strong and visible role of women professionals in MedTech, regulatory, engineering, and leadership positions
Events like MD&M West reinforce the importance of early regulatory involvement, cross-functional collaboration, and continuous learning in today’s MedTech environment.
We’re bringing these insights back into our work to support smarter regulatory strategies and sustainable compliance for medical and healthcare projects.

02/10/2026

Why the Biostatistics Symposium of Southern California (BSSC) Matters
The Alpi Solutions team recently attended the Biostatistics Symposium of Southern California (BSSC) — a serious scientific and applied forum focused on how modern biopharma actually works.
Key topics included:
✔ clinical trial design and statistics
✔ adaptive and Bayesian approaches
✔ oncology studies and real-world evidence
✔ AI and data science in clinical research
This was not about trends or buzzwords.
It was about how decisions made at the design and data level directly affect regulatory outcomes and patient impact.
At Alpi Solutions, we work exactly at this intersection — where science, statistics, and regulatory strategy come together.
📖 We’ve published a detailed breakdown of BSSC insights on Medium — link in comments.

01/15/2026

Biotech layoffs: what’s really happening?

According to the BioSpace Layoff Tracker, many biopharma companies and biotech startups are reducing staff in 2026 to cut costs and rethink their growth strategies.

This is more than a hiring issue — it’s a sign that companies need to streamline operations, focus their R&D pipelines, and build smarter, more efficient regulatory strategies to move forward in a tougher market.

In times like these, clarity and ex*****on matter more than scale.

Follow along as BioSpace tracks job cuts and restructuring initiatives.

01/08/2026

Pharma Outlook 2026: what will shape Pharma & Biotech this year

2026 is a year of strategic choices for pharma and biotech — not just scientific breakthroughs.

Here are a few key forces already shaping the industry:

🔹 Pricing pressure is becoming the new normal
Global cost-containment policies are pushing companies to clearly demonstrate value — earlier and more thoughtfully.

🔹 Real-world evidence matters more than ever
RWE is now a key part of market access, payer discussions, and long-term product strategy.

🔹 AI in market research: helpful tool, not a magic solution
AI can speed up analysis, but it still needs expert interpretation and context.

🔹 Faster regulatory pathways don’t mean simpler requirements
Acceleration still comes with higher expectations for evidence and planning.

The companies that succeed in 2026 will be those that think ahead and plan early.

At ALPI Solutions, we support pharma and biotech teams in navigating these shifts — from early insight to strategic ex*****on.

💬 Which of these trends do you see impacting your work the most in 2026?